Drugs / Eldelumab
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00295282 | Jan 2006 → Jan 2008 | ulcerative colitis | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 24 trials · 1 met primary · 3 missed | ||||||
| Phase 2 | NCT01466374 | Dec 2011 → Jun 2014 | Crohn disease | Bristol-Myers Squibb | Completed | Missed primary |
| Phase 2 | NCT01294410 | Mar 2011 → Dec 2012 | ulcerative colitis | Bristol-Myers Squibb | Completed | Missed primary |
| Phase 2 | NCT00656890 | Apr 2008 → Sep 2009 | ulcerative colitis | Bristol-Myers Squibb | Completed | Missed primary |
| Phase 2 | NCT01017367 | Feb 2008 → Jan 2009 | rheumatoid arthritis | Bristol-Myers Squibb | Completed | Met primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eldelumab | “Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study.” PMID 26721935 ↗ Dec 20151“Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy” PMID 28333187 ↗ Jul 2017 |
| Known as | BMS-936557 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109664 ↗ |
| Known as | MDX-1100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00656890 ↗ |
| Modality | Monoclonal antibody | “anti-CXCL10 human monoclonal antibody” NCT00295282 ↗ |
| Route | Intravenous | “60 minute intravenous infusion” NCT00295282 ↗ |
| Target | CXCL10 | “anti-CXCL10 human monoclonal antibody” NCT00295282 ↗ |